NR3C1 and cardiovascular disorder: In the context of personalized healthcare, this may implicate that, after treatment of CS, carriers of these polymorphisms are candidates for a more stringent follow-up regarding cardiovascular and metabolic health as our findings suggest that GR polymorphisms may play a role in susceptibility to cardiovascular disease in CS patients.